Código QR (código de barras bidimensional)

Cost-effectiveness of lurbinectedin with atezolizumab for extensive-stage small-cell lung cancer in the United States: impact of drug wastage reduction on economic outcomes

Abstract Background The IMforte trial had supported lurbinectedin as a recommended first-line maintenance therapy for patients with extensive-stage small-cell lung cancer (ES-SCLC), while its cost-effectiveness remains uncertain for patients and clinical decision-makers. This study aims to evaluate...

תיאור מלא

שמור ב:
Principais autores: Jiaming Zhu, Zhengxiong Li, Danlei Song, Wen Liu
פורמט: Artigo
שפה:Inglês
יצא לאור: BMC 2026-05-01
סדרה:BMC Health Services Research
נושאים:
Cost-effectiveness
Extensive-stage small-cell lung cancer
Lurbinectedin
Atezolizumab
Drug wastage and mitigation
גישה מקוונת:https://doi.org/10.1186/s12913-026-14653-5
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים